DNA viruses and genetic modification of dendritic cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 4, 2002, Pages 273-277

  Jenne, Lars ^a   Steinkasserer, Alexander ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Dermatology ^*  (Germany)

Author keywords

Dendritic cells; Gene therapy; Herpes simplex virus; Vaccinia virus; Viral vectors

Indexed keywords

ANIMAL; DENDRITIC CELL; DNA VIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HERPES VIRUS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; POXVIRUS; REVIEW; VIROLOGY;

ANIMALS; DENDRITIC CELLS; DNA VIRUSES; GENETIC THERAPY; GENETIC VECTORS; HERPESVIRIDAE; HUMANS; IMMUNOTHERAPY; POXVIRIDAE;

EID: 1842869160     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. ACE C. I., MCKEE T. A., RYAN J. M., CAMERON J. M. and PRESTON C. M. (1989): Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression. J. Virol., 63, 2260-2269.
2. ALCAMI A. and KOSZINOWSKI U. H. (2000): Viral mechanisms of immune evasion. Immunol. Today, 21, 447-455.
3. ALCAMI A. and SMITH G. L. (1992): A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell, 71, 153-167.
4. BROWN M., DAVIES D. H., SKINNER M. A., BOWEN G., HOLLINGSWORTH S. J., MUFTI G. J., ARRAND J. R. and STACEY S. N. (1999): Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther., 6, 238-245.
5. CARROLL M. W. and MOSS B. (1997): Poxviruses as expression vectors. Curr. Opin. Biotechnol., 8, 573-577.
6. CHOU J., KERN E. R., WHITLEY R. J. and ROIZMAN B. (1990): Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 250, 1262-1266.
7. DRILLIEN R., SPEHNER D., BOHBOT A. and HANAU D. (2000): Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology, 268, 471-481.
8. FINK D. J. and GLORIOSO J. C. (1997): Herpes simplex virus-based vectors: problems and some solutions. Adv. Neurol., 72, 149-156.
9. GELLER A. I. (1997): Herpes simplex virus-1 plasmid vectors for gene transfer into neurons. Adv. Neurol., 72, 143-148.
10. HARRIS N. L. and RONCHESE F. (1999): The role of B7 costimulation in T-cell immunity. Immunol. Cell Biol., 77, 304-311.
11. HAYWARD A. R., READ G. S. and COSYNS M. (1993): Herpes simplex virus interferes with monocyte accessory cell function. J. Immunol., 150, 190-196.
12. HOLZER G. W., REMP G., ANTOINE G., PFLEIDERER M., ENZERSBERGER O. M., EMSENHUBER W., HAMMERLE T., GRUBER F., URBAN C., FALKNER F. G. and DORNER F. (1999): Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J. Virol., 73, 4536-4542.
13. HORIG H., LEE D. S., CONKRIGHT W., DIVITO J., HASSON H., LAMARE M., RIVERA A., PARK D., TINE J., GUITO K., TSANG K. W., SCHLOM J. and KAUFMAN H. L. (2000): Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother., 49, 504-514.
14. IGNATIUS R., MAROVICH M., MEHLHOP E., VILLAMIDE L., MAHNKE K., COX W. I., ISDELL F., FRANKEL S., MASCOLA J. R., STEINMAN R. M. and POPE M. (2000): Canarypox-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor-α secretion. J. Virol., 74, 11329-11338.
15. JENNE L., HAUSER C., ARRIGHI J. F., SAURAT J. H. and HUGIN A. W. (2000): Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther., 7, 1575-1583.
16. JONULEIT H., GIESECKE-TUETTENBERG A., TUTING T., THURNER-SCHULER B., STUGE T. B., PARAGNIK L., KANDEMIR A., LEE P. P., SCHULER G., KNOP J. and ENK A. H. (2001): A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer, 93, 243-251.
17. KRUSE M., ROSORIUS O., KRATZER F., BEVEC D., KUHNT C., STEINKASSERER A., SCHULER G. and HAUBER J. (2000): Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J. Exp. Med., 191, 1581-1590.
18. KRUSE M., ROSORIUS O., KRATZER F., STELZ G., KUHNT C., SCHULER G., HAUBER J. and STEINKASSERER A. (2000): Mature dendritic cells infected with herpes simplex virus type I exhibit inhibited T cell stimulatory capacity. J. Virol., 74, 7127-7136.
19. KWONG A. D. and FRENKEL N. (1989): The herpes simplex virus virion host shutoff function. J. Virol., 63, 4834-4839.
20. MACKETT M. and SMITH G. L. (1986): Vaccinia virus expression vectors. J. Gen. Virol., 67, 2067-2082.
21. MARKERT J. M., MEDLOCK M. D., RABKIN S. D., GILLESPIE G. Y., TODO T., HUNTER W. D., PALMER C. A., FEIGENBAUM F., TORNATORE C., TUFARO F. and MARTUZA R. L. (2000): Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7, 867-874.
22. MEYER H., SUTTER G. and MAYR A. (1999): Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol., 72 (Pt 5), 1031-1038.
23. MIKLOSKA Z., BOSNJAK L. and CUNNINGHAM A. L. (2001): Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J. Virol., 75, 5958-5964.
24. MINETA T., RABKIN S. D., YAZAKI T., HUNTER W. D. and MARTUZA R. L. (1995): Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1, 938-943.
25. PARRY C. M., SIMAS J. P., SMITH V. P., STEWART C. A., MINSON A. C., EFSTATHIOU S. and ALCAMI A. (2000): A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med., 191, 573-578.
26. SALIO M., CELLA M., SUTER M. and LANZAVECCHIA A. (1999): Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol., 29, 3245-3253.
27. SENA-ESTEVES M., SAEKI Y., FRAEFEL C. and BKEAKEFIELD X. O. (2000): HSV-1 amplicon vectors - simplicity and versatility. Mol. Ther., 2, 9-15.
28. SUTTER G. and MOSS B. (1992): Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA, 89, 10847-10851.
29. SYDISKIS R. J. and ROIZMA B. (1966): Polysomes and protein synthesis in cells infected with a DNA virus. Science, 153, 76-78.
30. TOMAZIN R., VAN SCHOOT N. E., GOLDSMITH K., JUGOVIC P., SEMPE P., FRU K. and JOHNSON D. C. (1998): Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J. Virol., 72, 2560-2563.
31. TORTORELLA D., GEWURZ B. E., FURMAN M. H., SCHUST D. J. and PLOEGH H. L. (2000): Viral subversion of the immune system. Annu. Rev. Immunol., 18, 861-926.
32. WHITLEY R. (1996): Herpes simplex viruses. In FIELD B. N., KNIPE D. M. and HOWLEY P. M. (eds.): Fields virology. Lipincott-Raven, Philadelphia, 2297-2342.
33. ZACHOS G., CLEMENTS B. and CONNER J. (1999): Herpes simplex virus type 1 infection stimulates p38/c-Jun N-tenninal mitogen-activated protein kinase pathways and activates transcription factor AP-1. J. Biol. Chem., 274, 5097-5103.
34. ZHU M., TERASAWA H., GULLEY J., PANICALI D., ARLEN P., SCHLOM J. and TSANG K. Y. (2001): Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res., 61, 3725-3734.